Kubesch, A.; Kruse, N.; Jungheim, F.; Balaban, Ü.; Stratmann, K.; Sprinzl, K.; Dienethal, A.; Krause, T.; Zeuzem, S.; Blumenstein, I.
Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort. J. Clin. Med. 2023, 12, 7657.
https://doi.org/10.3390/jcm12247657
AMA Style
Kubesch A, Kruse N, Jungheim F, Balaban Ü, Stratmann K, Sprinzl K, Dienethal A, Krause T, Zeuzem S, Blumenstein I.
Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort. Journal of Clinical Medicine. 2023; 12(24):7657.
https://doi.org/10.3390/jcm12247657
Chicago/Turabian Style
Kubesch, Alica, Nina Kruse, Florian Jungheim, Ümniye Balaban, Katharina Stratmann, Kathrin Sprinzl, Antje Dienethal, Thomas Krause, Stefan Zeuzem, and Irina Blumenstein.
2023. "Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort" Journal of Clinical Medicine 12, no. 24: 7657.
https://doi.org/10.3390/jcm12247657
APA Style
Kubesch, A., Kruse, N., Jungheim, F., Balaban, Ü., Stratmann, K., Sprinzl, K., Dienethal, A., Krause, T., Zeuzem, S., & Blumenstein, I.
(2023). Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort. Journal of Clinical Medicine, 12(24), 7657.
https://doi.org/10.3390/jcm12247657
